NRAS and melanoma: To confirm our findings in additional and more clinically relevant models, we extended these observations to low-passage patient-derived melanoma cells carrying NRAS mutations that have been profiled using mRNA, qPCR, and DNA short tandem repeat analysis to confirm that they closely match the original patient tumor tissue (Table S3).